NEUROCRINE BIOSCIENCES INC

NASDAQ: NBIX (Neurocrine Biosciences, Inc.)

Kemas kini terakhir: 2 hari lalu, 4:28AM

120.18

1.06 (0.89%)

  • 1H 0.89%
  • 5H -0.69%
  • 1B 12.89%
  • 6B -5.06%
  • Tahun Ke Tarikh -12.82%
  • 1T -14.45%
  • 5T 0.90%
Penutupan Terdahulu 119.12
Buka 118.05
Jumlah Dagangan 882,148
Purata Dagangan (3B) 1,537,706
Modal Pasaran 11,893,709,824
Harga / Pendapatan (P/E TTM) 40.88
Harga / Pendapatan (P/E Ke hadapan) 21.46
Harga / Jualan (P/S) 5.21
Harga / Buku (P/B) 4.74
Julat 52 Minggu
84.23 (-29%) — 157.98 (31%)
Tarikh Pendapatan 30 Jul 2025 - 4 Aug 2025
Margin Keuntungan 14.49%
Margin Operasi (TTM) 20.87%
EPS Cair (TTM) 3.29
Pertumbuhan Hasil Suku Tahunan (YOY) 21.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -30.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 19.14%
Nisbah Semasa (MRQ) 3.40
Aliran Tunai Operasi (OCF TTM) 595.40 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 457.98 M
Pulangan Atas Aset (ROA TTM) 10.45%
Pulangan Atas Ekuiti (ROE TTM) 14.16%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menurun Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menurun Bercampur
Stok Neurocrine Biosciences, Inc. Menurun Menurun

AISkor Stockmoo

0.0
Konsensus Penganalisis -0.5
Aktiviti Orang Dalam NA
Volatiliti Harga 1.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal 2.0
Purata 0.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
NBIX 12 B - 40.88 4.74
LNTH 6 B - 15.19 6.42
ALVO 3 B - - -
KNSA 2 B - - 4.29
HROW 1 B - - 13.08
CRON 782 M - 14.50 0.650

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 1.08%
% Dimiliki oleh Institusi 99.17%
177.00177.00156.00156.00135.00135.00114.00114.0093.0093.00Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
84.23 (-29%) — 157.98 (31%)
Julat Harga Sasaran
115.00 (-4%) — 185.00 (53%)
Tinggi 185.00 (Evercore ISI Group, 53.94%) Beli
Median 154.00 (28.14%)
Rendah 115.00 (BMO Capital, -4.31%) Pegang
Purata 156.09 (29.88%)
Jumlah 10 Beli, 1 Pegang
Harga Purata @ Panggilan 115.22
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BMO Capital 06 May 2025 115.00 (-4.31%) Pegang 118.92
Canaccord Genuity 06 May 2025 160.00 (33.13%) Beli 118.92
28 Apr 2025 158.00 (31.47%) Beli 106.46
Guggenheim 06 May 2025 165.00 (37.29%) Beli 118.92
Needham 06 May 2025 139.00 (15.66%) Beli 118.92
15 Apr 2025 138.00 (14.83%) Beli 96.16
Piper Sandler 06 May 2025 154.00 (28.14%) Beli 118.92
RBC Capital 06 May 2025 145.00 (20.65%) Beli 118.92
14 Apr 2025 137.00 (14.00%) Beli 94.89
UBS 06 May 2025 152.00 (26.48%) Beli 118.92
04 Apr 2025 137.00 (14.00%) Beli 95.65
Evercore ISI Group 24 Apr 2025 185.00 (53.94%) Beli 105.76
HC Wainwright & Co. 22 Apr 2025 168.00 (39.79%) Beli 101.74
JP Morgan 26 Mar 2025 184.00 (53.10%) Beli 114.45
Morgan Stanley 07 Mar 2025 150.00 (24.81%) Beli 113.04
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
COOKE JULIE - - 0 0
Jumlah Keseluruhan Kuantiti Bersih 0
Jumlah Keseluruhan Nilai Bersih ($) 0
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) -
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
COOKE JULIE Pegawai 16 May 2025 Pelaksanaan pilihan 6,468 - -
  • 3M
Tarikh Jenis Butiran
16 May 2025 Pengumuman Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
16 May 2025 Pengumuman Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
15 May 2025 Pengumuman Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
14 May 2025 Pengumuman Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
08 May 2025 Pengumuman Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
06 May 2025 Pengumuman Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
06 May 2025 Pengumuman Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
05 May 2025 Pengumuman Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
05 May 2025 Pengumuman Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
30 Apr 2025 Pengumuman Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
24 Apr 2025 Pengumuman Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
14 Apr 2025 Pengumuman Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
04 Apr 2025 Pengumuman Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
31 Mar 2025 Pengumuman Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
20 Mar 2025 Pengumuman Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
17 Mar 2025 Pengumuman Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
11 Mar 2025 Pengumuman Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
05 Mar 2025 Pengumuman Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
27 Feb 2025 Pengumuman Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
Papar semua
125.54125.54119.33119.33113.12113.12106.91106.91100.70100.70May 14May 14May 15May 15May 16May 16May 19May 19May 20May 20May 21May 21May 22May 22May 23May 23

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
8.0008.0006.0006.0004.0004.0002.0002.0000.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda